pdli20130906

0001437749-13-011737.txt : 20130909 0001437749-13-011737.hdr.sgml : 20130909 20130909070225 ACCESSION NUMBER: 0001437749-13-011737 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20130909 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130909 DATE AS OF CHANGE: 20130909 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 131084234 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 8-K 1 pdli20130906_8k.htm FORM 8-K pdli20130906_8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 9, 2013

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)


Delaware		94-3023969
(State or Other Jurisdiction of		(I.R.S. Employer Identification No.)
Incorporation)

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Press Release

On September 9, 2013, PDL BioPharma, Inc. (the Company) issued a press release with revenue guidance for the third quarter ending September 30, 2013. A copy of the press release is attached hereto as Exhibit 99.1.

Detailed Product Sales, Royalties and Manufacturing

On September 9, 2013, the Company distributed to analysts covering the Company’s securities and posted to its website a summary of certain information underlying the Company’s receipt of royalty payments (the Information Sheet) to assist those analysts and its stockholders in valuing the Company’s securities. The Information Sheet is based on information provided to the Company by its licensees and includes reported net sales revenues by licensed product, royalty revenue by licensed product and where certain licensed products are manufactured and sold. A copy of the Information Sheet is attached hereto as Exhibit 99.2

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Current Report on Form 8-K, the information in Item 7.01 of this report, including Exhibits 99.1 and 99.2, is furnished and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Such information will not be deemed an admission as to the materiality of any such information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing, the press release, the Information Sheet and the Company’s statements herein and in the attached press release include and constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company’s royalty assets or business and limit the Company’s ability to pay dividends, purchase income generating assets and take other corporate actions are disclosed in the “Risk Factors” contained in the Company’s 2012 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2013, as updated by subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.		Description
99.1		Press Release

99.2		Information Sheet

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PDL BioPharma, inc.
	(Company)

	By:	/s/ Peter S. Garcia
		Peter S. Garcia
		Vice President, Chief Financial Officer and
		Chief Accounting Officer

Dated: September 9, 2013

Exhibit Index

Exhibit No.

Description

99.1

Press Release

99.2

Information Sheet

EX-99 2 ex99-1.htm EXHIBIT 99.1 ex99-1.htm

Exhibit 99.1

Contacts:

Peter S. Garcia

Jennifer Williams

PDL BioPharma, Inc.

Cook Williams Communications, Inc.

775-832-8500

360-668-3701

Peter.garcia@pdl.com

Jennifer@cwcomm.org

PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million

INCLINE VILLAGE, NV, September 9, 2013 – PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the third quarter ending September 30, 2013, of approximately $97 million, as compared with actual revenue of $85 million for the third quarter of 2012, an approximate 14 percent increase.

The forecasted growth in revenues is driven by increased second quarter 2013 sales for Avastin^®, Herceptin^®, Lucentis^®, Xolair^®, Kadcyla^®, Perjeta^®, and Actemra^® for which PDL receives royalties in the third quarter of 2013. Sales of Avastin^®, Herceptin^®, Lucentis^®, Xolair^®, Perjeta^®, and Kadcyla^® (the Genentech Products) are subject to a tiered royalty rate for product that is made or sold in the United States and a flat royalty rate of three percent for product that is manufactured and sold outside of the United States (ex-US manufactured and sold). The net sales thresholds and the applicable royalty rates for the Genentech Products are outlined below:

Genentech Products Made or Sold in US	Royalty Rate
Net sales up to $1.5 billion	3.0%
Net sales between $1.5 billion and up to $2.5 billion	2.5%
Net sales between $2.5 billion and up to $4.0 billion	2.0%
Net sales exceeding $4.0 billion	1.0%

Genentech Products Made and Sold ex-US
Net sales	3.0%

The third quarter royalty payment received from Genentech included royalties based on worldwide sales.

Revenue guidance for the third quarter of 2013 is net of an estimated payment due under our February 2011 settlement agreement with Novartis AG (Novartis). PDL pays to Novartis certain amounts based on net sales of Lucentis, made by Novartis, during calendar year 2011 and beyond. The amount paid is less than we receive in royalties on such sales.

Reported worldwide sales for Avastin sales increased approximately 13 percent in the second quarter of 2013 when compared to the same period in 2012. Ex-U.S. manufactured and sold Avastin sales represented 38 percent of total Avastin sales in the second quarter of 2013 as compared with 29 percent in the second quarter of 2012.

Reported worldwide sales for Herceptin increased approximately 1 percent in the second quarter of 2013 when compared to the same period in 2012. Ex-U.S. manufactured and sold Herceptin sales represented 38 percent of total Herceptin sales in the second quarter of 2013 as compared with 37 percent in the second quarter of 2012.

Reported worldwide sales for Lucentis increased approximately 9 percent in the second quarter of 2013 when compared to the same period in 2012. All sales of Lucentis were from inventory produced in the United States.

Reported worldwide sales for Tysabri^®, a Biogen Idec product, decreased approximately 1 percent for the second quarter of 2013 compared to the same period in 2012. Tysabri royalties are determined at a flat rate as a percentage of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL’s licensees in their quarterly reports to the Company as well as from public disclosures made by PDL’s licensees.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new income generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

●

The expected rate of growth in royalty-bearing product sales by PDL’s existing licensees;

●

The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;

●

The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, will be commercially successful;

●

The productivity of acquired income generating assets may not fulfill our revenue forecasts and, if secured by collateral, we may be undersecured and unable to recuperate our capital expenditures in the transaction;

●

Changes in any of the other assumptions on which PDL’s projected royalty revenues are based;

●

The outcome of pending litigation or disputes, including PDL’s current dispute with Genentech related to ex-U.S. sales of Genentech licensed products;

●

The change in foreign currency exchange rate;

●

Positive or negative results in PDL’s attempt to acquire income generating assets; and

●

The failure of licensees to comply with existing license agreements, including any failure to pay royalties due.

Other factors that may cause PDL's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are discussed in PDL's filings with the SEC, including the "Risk Factors" sections of its annual report filed with the SEC. Copies of PDL's filings with the SEC may be obtained at the "Investors" section of PDL's website at www.pdl.com. PDL expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in PDL's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based for any reason, except as required by law, even as new information becomes available or other events occur in the future. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.

EX-99 3 ex99-2.htm EXHIBIT 99.2 ex99-2.htm

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *

Avastin

Q1

Q2

Q3

Q4

Total

2013
33,234 46,720 32,224 - 112,177

2012
23,215 41,670 25,955 30,041 120,882

2011
22,283 41,967 23,870 22,886 111,006

2010
16,870 44,765 29,989 24,922 116,547

2009
13,605 35,161 21,060 15,141 84,966

2008
9,957 30,480 19,574 12,394 72,405

2007
8,990 21,842 17,478 9,549 57,859

2006
10,438 15,572 15,405 12,536 53,952

Herceptin

Q1

Q2

Q3

Q4

Total

2013
30,287 47,353 30,961 - 108,602

2012
25,702 44,628 30,433 28,307 129,070

2011
25,089 42,209 31,933 21,812 121,042

2010
23,402 38,555 27,952 25,441 115,350

2009
16,003 32,331 26,830 18,615 93,779

2008
14,092 34,383 28,122 20,282 96,880

2007
19,035 28,188 22,582 14,802 84,608

2006
15,142 19,716 21,557 20,354 76,769

Lucentis

Q1

Q2

Q3

Q4

Total

2013
12,032 30,066 13,536 - 55,633

2012
10,791 27,938 12,552 11,097 62,377

2011
8,878 24,313 12,157 10,750 56,099

2010
7,220 19,091 10,841 8,047 45,198

2009
4,621 12,863 8,123 6,152 31,759

2008
3,636 11,060 7,631 4,549 26,876

2007
2,931 6,543 6,579 3,517 19,570

2006
- - 289 3,335 3,624

Xolair

Q1

Q2

Q3

Q4

Total

2013
5,930 10,025 7,334 - 23,288

2012
5,447 8,609 6,504 6,145 26,705

2011
4,590 7,621 5,916 5,823 23,949

2010
3,723 6,386 4,980 4,652 19,741

2009
2,665 5,082 4,085 3,722 15,553

2008
1,488 4,866 3,569 2,927 12,850

2007
1,684 3,942 3,332 2,184 11,142

2006
2,263 2,969 3,041 2,495 10,768

Perjeta

Q1

Q2

Q3

Q4

Total

2013
340 1,414 748 - 2,502

2012
- - 58 250 308

2011
- - - - -

2010
- - - - -

2009
- - - - -

2008
- - - - -

2007
- - - - -

2006
- - - - -

Kadcyla

Q1

Q2

Q3

Q4

Total

2013
- 551 830 - 1,381

2012
- - - - -

2011
- - - - -

2010
- - - - -

2009
- - - - -

2008
- - - - -

2007
- - - - -

2006
- - - - -

Tysabri

Q1

Q2

Q3

Q4

Total

2013
12,965 13,616 11,622 - 38,203

2012
11,233 12,202 11,749 12,255 47,439

2011
9,891 10,796 11,588 11,450 43,725

2010
8,791 8,788 8,735 9,440 35,754

2009
6,656 7,050 7,642 8,564 29,912

2008
3,883 5,042 5,949 6,992 21,866

2007
839 1,611 2,084 2,836 7,370

2006
- - - 237 237

Actemra

Q1

Q2

Q3

Q4

Total

2013
2,631 2,816 2,939 - 8,386

2012
1,705 2,074 2,145 2,462 8,385

2011
913 1,136 1,401 1,460 4,910

2010
1,587 237 315 688 2,827

2009
585 537 909 1,197 3,228

2008
44 - 146 369 559

2007
32 - - 17 49

2006
- - - - -

* As reported to PDL by its licensees

Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin

Q1

Q2

Q3

Q4

Total

2013
1,653,108 1,694,678 1,746,135 - 5,093,921

2012
1,502,757 1,573,727 1,551,327 1,662,977 6,290,788

2011
1,597,461 1,582,705 1,581,095 1,469,994 6,231,255

2010
1,506,788 1,596,892 1,594,707 1,646,218 6,344,605

2009
1,345,487 1,295,536 1,439,730 1,514,053 5,594,806

2008
980,715 1,084,930 1,180,427 1,239,382 4,485,454

2007
678,068 746,587 797,013 875,084 3,096,752

2006
439,318 516,052 570,551 592,897 2,118,817

Herceptin

Q1

Q2

Q3

Q4

Total

2013
1,681,574 1,744,145 1,681,860 - 5,107,579

2012
1,515,255 1,625,313 1,663,695 1,650,495 6,454,759

2011
1,391,568 1,559,975 1,642,898 1,432,771 6,027,211

2010
1,270,846 1,349,512 1,300,934 1,409,310 5,330,602

2009
1,210,268 1,133,993 1,226,435 1,278,626 4,849,323

2008
1,105,426 1,195,215 1,211,982 1,186,806 4,699,428

2007
891,761 949,556 979,602 1,015,033 3,835,952

2006
529,585 659,719 761,099 803,576 2,753,979

Lucentis

Q1

Q2

Q3

Q4

Total

2013
1,203,179 1,171,423 1,200,791 - 3,575,394

2012
1,079,092 1,086,543 1,097,541 1,109,695 4,372,871

2011
887,757 943,418 1,052,809 1,075,015 3,958,999

2010
721,967 698,890 745,376 804,684 2,970,917

2009
462,103 469,736 555,296 615,212 2,102,347

2008
363,615 393,682 460,167 454,922 1,672,386

2007
224,820 219,579 299,995 322,300 1,066,695

2006
- - 10,689 157,742 168,431

Xolair

Q1

Q2

Q3

Q4

Total

2013
341,309 365,778 391,900 - 1,098,987

2012
310,234 314,638 347,796 340,431 1,313,100

2011
267,754 277,642 310,874 314,911 1,171,182

2010
228,859 225,878 251,055 263,389 969,179

2009
184,669 181,086 211,006 219,693 796,454

2008
137,875 169,521 177,179 183,753 668,329

2007
129,172 130,700 144,250 147,754 551,876

2006
95,241 99,354 112,608 118,002 425,204

Perjeta

Q1

Q2

Q3

Q4

Total

2013
34,008 55,076 66,353 - 155,437

2012
- - 5,080 25,000 30,079

2011
- - - - -

2010
- - - - -

2009
- - - - -

2008
- - - - -

2007
- - - - -

2006
- - - - -

Kadcyla

Q1

Q2

Q3

Q4

Total

2013
- 21,459 73,626 - 95,085

2012
- - - - -

2011
- - - - -

2010
- - - - -

2009
- - - - -

2008
- - - - -

2007
- - - - -

2006
- - - - -

Tysabri

Q1

Q2

Q3

Q4

Total

2013
434,677 451,358 387,407 - 1,273,442

2012
374,430 401,743 391,623 408,711 1,576,508

2011
329,696 356,876 388,758 381,618 1,456,948

2010
293,047 287,925 293,664 316,657 1,191,292

2009
221,854 229,993 257,240 285,481 994,569

2008
129,430 163,076 200,783 233,070 726,359

2007
30,468 48,715 71,972 94,521 245,675

2006
- - - 7,890 7,890

Actemra

Q1

Q2

Q3

Q4

Total

2013
87,703 91,374 97,961 - 277,038

2012
56,662 66,624 71,505 82,053 276,843

2011
30,433 35,370 46,709 48,671 161,183

2010
52,908 5,405 10,493 22,919 91,725

2009
19,504 17,920 30,313 39,888 107,625

2008
1,452 1,377 5,981 12,305 21,115

2007
- - - 1,137 1,137

2006
- - - - -

* As reported to PDL by its licensee. Dates in above charts reflect when PDL receives royalties on sales. Sales occurred in the quarter prior to the dates in the above charts.

Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		724,483			679,914			710,501			664,109			750,491			716,337
US Made & ex-US Sold		532,979			428,976			281,905			161,369			165,651			360,177
ex-US Made & Sold		316,265			442,437			670,572			827,629			778,536			669,621
Total		1,573,727			1,551,327			1,662,977			1,653,108			1,694,678			1,746,135
US Made & Sold		46	%		44	%		43	%		40	%		44	%		41	%
US Made & ex-US Sold		34	%		28	%		17	%		10	%		10	%		21	%
ex-US Made & Sold		20	%		29	%		40	%		50	%		46	%		38	%

Herceptin Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		497,109			503,612			515,790			514,113			583,677			518,790
US Made & ex-US Sold		466,477			545,625			552,127			486,400			563,243			522,159
ex-US Made & Sold		661,727			614,459			582,578			681,060			597,225			640,911
Total		1,625,313			1,663,695			1,650,495			1,681,574			1,744,145			1,681,860
US Made & Sold		31	%		30	%		31	%		31	%		33	%		31	%
US Made & ex-US Sold		29	%		33	%		33	%		29	%		32	%		31	%
ex-US Made & Sold		41	%		37	%		35	%		41	%		34	%		38	%

Lucentis Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		412,131			385,746			381,592			392,207			419,030			449,834
US Made & ex-US Sold		674,411			711,795			728,103			810,972			752,393			750,958
ex-US Made & Sold		-			-			-			-			-			-
Total		1,086,543			1,097,541			1,109,695			1,203,179			1,171,423			1,200,791
US Made & Sold		38	%		35	%		34	%		33	%		36	%		37	%
US Made & ex-US Sold		62	%		65	%		66	%		67	%		64	%		63	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%

Xolair Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		193,600			211,702			210,892			207,976			218,860			236,180
US Made & ex-US Sold		-			-			-			-			-			-
ex-US Made & Sold		121,039			136,094			129,540			133,333			146,918			155,720
Total		314,638			347,796			340,431			341,309			365,778			391,900
US Made & Sold		62	%		61	%		62	%		61	%		60	%		60	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		0	%
ex-US Made & Sold		38	%		39	%		38	%		39	%		40	%		40	%

Perjeta Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		-			5,080			24,571			32,377			48,979			49,111
US Made & ex-US Sold		-			-			428			1,632			6,096			17,242
ex-US Made & Sold		-			-			-			-			-			-
Total		-			5,080			25,000			34,008			55,076			66,353
US Made & Sold		0	%		100	%		98	%		95	%		89	%		74	%
US Made & ex-US Sold		0	%		0	%		2	%		5	%		11	%		26	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%

Kadcyla Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		-			-			-			-			21,459			72,887
US Made & ex-US Sold		-			-			-			-			-			739
ex-US Made & Sold		-			-			-			-			-			-
Total		-			-			-			-			21,459			73,626
US Made & Sold		0	%		0	%		0	%		0	%		100	%		99	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		1	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%

Total Sales	2012 - Q2			2012 - Q3			2012 - Q4			2013 - Q1			2013 - Q2			2013 - Q3
US Made & Sold		1,827,323			1,786,053			1,843,345			1,810,783			2,042,496			2,043,139
US Made & ex-US Sold		1,673,867			1,686,395			1,562,564			1,460,373			1,487,383			1,651,276
ex-US Made & Sold		1,099,031			1,192,990			1,382,690			1,642,023			1,522,679			1,466,252
Total		4,600,221			4,665,438			4,788,598			4,913,178			5,052,559			5,160,667
US Made & Sold		40	%		38	%		38	%		37	%		40	%		40	%
US Made & ex-US Sold		36	%		36	%		33	%		30	%		29	%		32	%
ex-US Made & Sold		24	%		26	%		29	%		33	%		30	%		28	%

* As reported to PDL by its licensee. Dates in above charts reflect when PDL receives royalties on sales. Sales occurred in the quarter prior to the dates in the above charts.

Totals may not sum due to rounding

GRAPHIC 4 logo.jpg begin 644 logo.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_[0NF4&AO=&]S:&]P(#,N,``X0DE-`^T` M`````!``2`````$``0!(`````0`!.$))300-```````$````>#A"24T#\P`` M````"```````````.$))300*```````!```X0DE-)Q````````H``0`````` M```".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9F@`& M```````!`#(````!`%H````&```````!`#4````!`"T````&```````!.$)) M30/X``````!P``#_____________________________`^@`````________ M_____________________P/H`````/____________________________\# MZ`````#_____________________________`^@``#A"24T$`````````@`! M.$))300"```````$`````#A"24T$"```````$`````$```)````"0``````X M0DE-!!0```````0````".$))300,``````GX`````0```'`````S```!4``` M0O````G<`!@``?_8_^``$$I&248``0(!`$@`2```_^X`#D%D;V)E`&2````` M`?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X. M#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M_\``$0@`,P!P`P$B``(1`0,1`?_=``0`!__$`3\```$%`0$!`0$!```````` M``,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``! M!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4 MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($ M!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\` M]55#,ZYTK!SL;`RLAM65F&*:SW[-WGZ-7J/_`$=7J?SMOZ.M4/K5]:L?H.,& M,`NZC<#]GQR=`./7OV_0H9_X-_-U_P#!^595]^;?;DYEAOOR#-UCN7'CC\QC M?HUUM_FU-BP\>ITCT4^V9V6S"Q;,JQI#E-=627-M9,.!:QU@U_LJ.4>&1B>BG<_YV87^@N^YO_DU?Z?U?"ZA M(H<18T2ZIXVO`_>C\YO]14G_`%5Z>6$,?:QT>UVX&#_5(7,BR[#R/48Z+L9Y MAS>"6$M=_8>FJ>PZGUG'Z:^MEM;WFT$C9':.=SF_O*G_`,[,+_07?'VX;QPZMQ'S+$'HG1\?J5=SKK+&&IP:/3+1H1NUWL>DIU:_K5TUS@'MM MJ'[Q;('_`&VY[O\`HK5HR*,BH6T/;96[AS3(7-]3^K8Q<9^3BVNL;4-UE=D3 MM'TG->P,^A_553H.:_$ZC6T']%DN%=C>Q)TJ?_6WI*>@ZCU[&Z?D_9[:['NV M!\L`B'%S?SG-_<5CIO4:NHT&^IKF-:\L(?$R(_=+OWESGUH_Y6'_`!#/^JM6 MI]5/^37_`/'/_(Q)3M))))*?_]#6^O?U3O\`6NZ]@[[@\`YM!)WF6N'(\"O=UQ75O\7-.5U9F1@W#$P;W%V92T>YI^D78 M6FQGK?N/]E'\[7_H59PYP!PSZ;%3<^J'UH.=T:U^=3Z/[-#:GY#&;:;!'L%+ M6_0N;[6W8]?L9^CV?SOI5TLOK&3?U`9[(I?4"VD0"6M.YOO_`'W.WKHLWI== M/0G=-Z;2&,8UK::6P!`WAKC^<5!,@R)`H'HIJ/^L/57M+3D@!P@EK6@_)VWVJ/2^E7]0N:T,DZSU'%Q\&Y MA>UUUK',KK!!)+AMDM_<;/N7*]-J=9U#%K9J?58?DP^H\_YC%8K^KO5B8&.V ML>)>T#_H%RW^C=#9T\FZUPMR7#;N`AK1W;7/[WYSTE.-]:/^5A_Q#/\`JK5I M?5>VIG3GA[VM)N?H2!V8J_7^E]0RNHB['I-E?I,;NW-&H=82/>YO[RS3]7^K M'4XDGS=7_P"324]E]IQ_]*S_`#@I,>QXEC@X<2#*XO\`YO=5_P"XG_2K_P#) MKHOJ[AY&%@NJR*_2>;7.#9!T(;K[)24__]'U5))))3D?6SJ.7TSZO9F=AD-R M*&M-9(W"2]C#[3_)L6];QL%V;C=:QS,##:'9%[6BL$[1H]CS[C_):L?I_1.LV M=;Z?FV85'1\?I['-N-%H?9D[F[`RUE-==?IL>/4_2_V%+#AX#=7ZM]_E]/\` M64WNG?6'#QND9G4<_/LR*:,NVGU+*A6X$.#&8E--&[U]KO94_P#G+5;Z9]9, M'J.4_"%=^'FL9ZOV;+J=38ZN=OK5M?[;&;OW?H+`'U5ZN[H5M(;6S-HZJ_J6 M+4]VZNQH?OKJM!UOJ7UCQ^M=2Q&=-JP*+*::!:VZRQ]OTWO?2/ M3;0QOT&?OHF,-3??K_B^E3B8OUM^L-'3L#J^3EXN75F9/V9_3A5Z=X'J&C?1 M8RWWO_PGNI5_%^M)Z?U;KS,]V3F5X][33316;?1I:S==:[:&LIH:[_26*Y]4 M?JKC]-Z?1;U#!QV]6K=9NR`&O?!>YU7Z>/\`1;$L3HG4*KOK,]];8ZH?U0[@ M=P])]7O_`-'^D=^_Z+:6^[_#.K0#];>D-Z2[JSO5;17<,:ZMU9;;5:7-J=7?39L=7Z;G_`*18 MCNB?63'Z5T3&;4_(Q\.EU>?T_'RCBO=80/1L^UUNJ]2FK_1^I_VX@W_57KC_ M`*N]4Z?Z-9R,KJ+,FEHM+VFK=2]\W7_I7;?3?_/?I'H"&/2Y=>_Z/$IWC]I MBN(RL?[.XVTM'^&R6_0JJ_ZXC_6#I69G=3Z)D8S&NIP\>[]"^GW_Z+]([\Y`#'0)_/^MPJ=7-Z]C8U&-=3 M1DYS!UO"ZC31=B"Q[+W/89:6NK?4= MMM6179MLJL:]NW9M7/Y72/K"RKHU3:;,K#Q<-E&3A499Q",AH8WU[;ZC6[(Q MV;=OIM?_`-;>M/ZH=*S^EX.51GL8RRS,NN8*WFQI99M'0`````0V]P>7)I9VAT M("AC*2`Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C```````` M`!)S4D="($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M M,BXQ```````````````````````````````````````````````````````` M``````````!865H@````````\U$``0````$6S%A96B`````````````````` M````6%E:(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA9 M6B`````````DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\` MI`"I`*X`L@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9 M`1\!)0$K`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$! MN0'!`$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z M`H0"C@*8`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8# M<@-^`XH#E@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2, M!)H$J`2V!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4% MY07V!@8&%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&09!ZP'OP?2!^4'^`@+"!$,@A&"%H(;@B"")8(J@B^"-((YPC["1`) M)0DZ"4$9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+ M"R(+.0M1"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28- M0`U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6 M#[,/SP_L$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$)%ZX7TA?W&!L8 M0!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&SL;8QN* M&[(;VAP"'"H<4AQ['*,0!YJ'I0>OA[I'Q,? M/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B--@U$S5- M-8Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y& M(D9G1JM&\$25^!8+UA]6,M9&EEI M6;A:!UI66J9:]5M%6Y5;Y5PU7(9O5\/7V%?LV`%8%=@ MJF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I M:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAO MT7`K<(9PX'$Z<95Q\')+%V/G:;=OAW5G>S M>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6` M1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C. MB3.)F8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2 M$9)ZDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M" MFZ^<')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E M.*6IIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:QK_UP'#`[,%GP>/"7\+;PUC#U,11 MQ,[%2\7(QD;&P\=!Q[_(/%$XIZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9 M\Z?T-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW_ M___N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3 M$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+ M#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#/_``!$(`$4`F0,!(@`"$0$#$0'_W0`$``K_Q`$_ M```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!```````` M``$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B M<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V M%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G M=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1 M%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1E MXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>G MM\?_V@`,`P$``A$#$0`_`/54DER?UP^N#>FM=T_I[@[.<(LL&HJ!_P#1W_4) MT8F1H*>K:YKIVD&#!C6".RC;;736ZVUP8QOTG'@+R;ZN?6?,Z+F&QQ=?C7NG M)J)DDGFUA=_AO_/B]&S\W%S^@6Y>)8+*;&@MQG&XC3[U/I_4LC`N#ZR2PGWUGAP_\E_*2 M4]M;;756ZRQP:QHESCP`JO[9Z7_W)8H=3N9?T6ZZLRRROU[':AS6.((\B`H6T7TZ6UNK/\ MMI;_`-4DI[\$$2#(/!"=75F8[,BKZ+QP>0 M?SFE)2-_5NG5O=6_(8U["6N![$:$(F-F8N5N^SV"S9&[;VGC\BXOJ7_*&5_Q MUG_5.6S]4?\`M7_UO_T8DIZ)))))2DDDDE/_T.J^N/UO'2VNZ?@&<]P_2/[5 M`B1_UYS?H+S5SG/<7O)22O5?K5]5:.MT>M3%74*A^CLX#P/\%; M_P!\?^8O+[3^XY=+TS_`).Q?^*9_P!2%RG5>JV]0MDRRAA_1U_]^=_+ M507WM`#;'`#@!Q513V_4;**\&XWQZ9800>Y(]K1_*7"*3[+'_3U MH\A"XM)3W'2/^3,;_BPK%U%5]3JKFA['"""J_2/^3,;_`(L(F7G8V'6;+WAL M<-_.)\&M24\3ET?9\JVB9]-[F@GN`="M[ZIVN->123HTM'WA)3)),"")!D>*=)3_`/_1]57._6OZJ4]:I-]`%?4*Q['\!X'^ M"M_[X]=$DC&1B;"GS#ZM_4O,ZAF.=U&M^/B8[]MH<"USW#_!5_R?W[5WO5Z: MJ.B74TL%=5;&M8QH@`!S=`M)!S+\7'QGW9CFLQV#](Y^K0)CW?VDZ>24SK]` MIX%=ITS$Q7=.QW.IKU-X975%38^Q88_P%?^8W^Y%````$`<`)TD%- M+K/_`"7D_P!1<0NQROK#T&FU^)E9=3;&G;96_L?!TC:GOR>BT].LZDUE-^+4 MW<7TM8^0/W8]J/"=-#JIXU)=KT\],ZAA59M&.P57#ZJEUSVAX<`UC?5KG]_P#>5)W3/KC=T2OH/V3'IQ]K M:WWNL#G0UWJ3[7.V^X?Z-7>K_5K-=TWH^%A@7?L^QIN>2&Z"-SQO/[WYJG,H MDBR/FEUXE-GKG7>HMZMC]"Z.VO[9>W?9=:"6,;[G?1'\EB%A=:ZS@=;IZ-UO MTKOM3=V-E4C;)U]KVZ?N_NJ76^C=4KZW1U_H[&7WUL].[&>X,WMAS=S7NVM^ MB[]Y"QND];ZKU['ZOUBAF%3A-_08S7BQQ=JX.1PL_ZSX?U5HZCB&BK"Q6P*G`NLL;O+ M'6._-:W>[Z*Z9_4L[+Z!1U#!=1CW7M8Y[\@D55@_SIG^2[Z"J?L;/_YE_LG8 M/MGH[-FX1NW[_ISL^BJ/4OJYU>[ZN]*Q:JVVW8+@[(PW/`;9_)]2=GM_K_GI M$QD>@]9_Q5,L'ZQ]2Q^M8N!EYN)U/'S26BW%(+JW?F[_`$_;])+/Z_\`6`_6 M7+Z)TUM3R&,]`V"`R65766V._/\`I/4#T;K65U3I>>.G4=.Q\2V7X]3F;FME MFZQ[F;&/W?F,9]!:&+T;.K^NF9U9[`,.ZD,K?N$EP;0SZ$[_`/!6)'@!OT_* M=/ZUJ:O5.N=?P>J=+Z97Z5N1E4,%X<(:;G;JW6;VC=Z3+!ZGM:A5=;^M5?6K M>@V'&NRGM#JLF"UC&QZCGN8T;G^SV;?](M#JO1\_)^M73>I5,!Q<9FVU^X`@ MS9^83N=]-(='SQ] MLY@^@Q7,#HO4:?K#U;.T.!.[V^[8#N]L+&POJ]UW'Z?D]+_`&7C M&ZT6`]3>]CG%K@1M8W6[>[Z-?\WZ:(X+)].T=-/\)3T_2NH9?5,/"ZA7%=5S M)N8(/N! M.M.&Z_P;4__3]527RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?J DI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9 ` end

Contacts:
Peter S. Garcia	Jennifer Williams
PDL BioPharma, Inc.	Cook Williams Communications, Inc.
775-832-8500	360-668-3701
Peter.garcia@pdl.com	Jennifer@cwcomm.org

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2013		33,234		46,720		32,224		-		112,177
2012		23,215		41,670		25,955		30,041		120,882
2011		22,283		41,967		23,870		22,886		111,006
2010		16,870		44,765		29,989		24,922		116,547
2009		13,605		35,161		21,060		15,141		84,966
2008		9,957		30,480		19,574		12,394		72,405
2007		8,990		21,842		17,478		9,549		57,859
2006		10,438		15,572		15,405		12,536		53,952

Herceptin	Q1		Q2		Q3		Q4		Total
2013		30,287		47,353		30,961		-		108,602
2012		25,702		44,628		30,433		28,307		129,070
2011		25,089		42,209		31,933		21,812		121,042
2010		23,402		38,555		27,952		25,441		115,350
2009		16,003		32,331		26,830		18,615		93,779
2008		14,092		34,383		28,122		20,282		96,880
2007		19,035		28,188		22,582		14,802		84,608
2006		15,142		19,716		21,557		20,354		76,769

Lucentis	Q1		Q2		Q3		Q4		Total
2013		12,032		30,066		13,536		-		55,633
2012		10,791		27,938		12,552		11,097		62,377
2011		8,878		24,313		12,157		10,750		56,099
2010		7,220		19,091		10,841		8,047		45,198
2009		4,621		12,863		8,123		6,152		31,759
2008		3,636		11,060		7,631		4,549		26,876
2007		2,931		6,543		6,579		3,517		19,570
2006		-		-		289		3,335		3,624

Xolair	Q1		Q2		Q3		Q4		Total
2013		5,930		10,025		7,334		-		23,288
2012		5,447		8,609		6,504		6,145		26,705
2011		4,590		7,621		5,916		5,823		23,949
2010		3,723		6,386		4,980		4,652		19,741
2009		2,665		5,082		4,085		3,722		15,553
2008		1,488		4,866		3,569		2,927		12,850
2007		1,684		3,942		3,332		2,184		11,142
2006		2,263		2,969		3,041		2,495		10,768

Perjeta	Q1		Q2		Q3		Q4		Total
2013		340		1,414		748		-		2,502
2012		-		-		58		250		308
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-

Kadcyla	Q1		Q2		Q3		Q4		Total
2013		-		551		830		-		1,381
2012		-		-		-		-		-
2011		-		-		-		-		-
2010		-		-		-		-		-
2009		-		-		-		-		-
2008		-		-		-		-		-
2007		-		-		-		-		-
2006		-		-		-		-		-

Tysabri	Q1		Q2		Q3		Q4		Total
2013		12,965		13,616		11,622		-		38,203
2012		11,233		12,202		11,749		12,255		47,439
2011		9,891		10,796		11,588		11,450		43,725
2010		8,791		8,788		8,735		9,440		35,754
2009		6,656		7,050		7,642		8,564		29,912
2008		3,883		5,042		5,949		6,992		21,866
2007		839		1,611		2,084		2,836		7,370
2006		-		-		-		237		237

Actemra	Q1		Q2		Q3		Q4		Total
2013		2,631		2,816		2,939		-		8,386
2012		1,705		2,074		2,145		2,462		8,385
2011		913		1,136		1,401		1,460		4,910
2010		1,587		237		315		688		2,827
2009		585		537		909		1,197		3,228
2008		44		-		146		369		559
2007		32		-		-		17		49
2006		-		-		-		-		-